23 Jul, 2026
According to Straits Research the global continuous blood glucose monitoring market was valued at $13.64 billion in 2025 and is anticipated to grow from $15.66 billion in 2026 to $48.51 billion by 2034, registering a CAGR of 15.18% during the forecast period 2026–2034.The demand for continuous glucose monitors (CGM) is rising. People with diabetes are among the most vulnerable to severe complications caused by COVID-19. During the COVID-19 pandemic, there has been more preference for the use of virtual clinics and telemedicine to monitor diabetics. For example, the UK's National Health Service revised its clinical guidance to promote remote contacts through mobile, email, and video conferencing. This has contributed to increased demand for apps for diabetic treatment, that can exchange data remotely.
With CGM tools, there is considerably more data available, which can help patients and healthcare providers enhance glycemic control and eventually increase patients' self-management. CGM's increasing demand is driven mainly by growing product awareness and rapid responses from companies to the COVID-19 pandemic. Both Dexcom and Abbott have been given FDA clearance to make available CGM systems for use in hospital settings and other health care facilities. Health Canada recently announced the Dexcom G6 CGM program's provisional authorization for the expanded use of Canadian hospitals.
Remote monitoring of patients with diabetes with CGM devices will help minimize healthcare providers' exposure and conserve personal protective equipment. Along with the insulin giants Novo Nordisk and Eli Lilly, CGM firms have launched new patient aid services to help existing CGM patients who have lost insurance due to the US COVID-19 pandemic. Dexcom has reduced its CGM costs for its current, eligible patients to USD 45 per 90-day supply. The pandemic has increased demand for the establishment of electronic blood glucose records for diabetes patients. COVID-19 has opened up new possibilities for CGM systems to gain popularity in the diabetic care brand.
The continuous blood glucose monitoring (CGM) market is driven by the rising prevalence of diabetes and the growing demand for real-time glucose monitoring solutions that improve disease management and patient outcomes. Increasing awareness of the benefits of continuous glucose monitoring, including enhanced glycemic control, reduced risk of complications, and improved self-management, has accelerated the adoption of CGM devices among patients and healthcare providers. The integration of CGM systems with mobile applications and digital health platforms has further strengthened market growth.
The market also witnessed significant momentum during the COVID-19 pandemic, as healthcare providers increasingly adopted telemedicine and remote patient monitoring to manage individuals with diabetes. The growing use of virtual consultations and cloud-connected CGM devices enabled healthcare professionals to monitor patients remotely while reducing hospital visits. Regulatory approvals for the use of CGM systems in hospitals and healthcare facilities further expanded their clinical applications and accelerated product adoption.
Furthermore, continuous technological advancements, supportive reimbursement initiatives, and strategic collaborations among medical device manufacturers and healthcare organizations are contributing to market expansion. The integration of CGM devices with insulin delivery systems, artificial intelligence, and digital diabetes management platforms is improving treatment efficiency and patient convenience. As demand for remote healthcare, connected medical devices, and personalized diabetes management continues to rise, the continuous blood glucose monitoring market is expected to witness sustained long-term growth.
sales@straitsresearch.com